CD274 and non-small cell lung carcinoma: For instance, pembrolizumab in combination with chemotherapy in PD-L1 high non-small cell lung cancer (NSCLC) patients (TPS > 1%) demonstrated better clinical activity compared to PD-L1 low NSCLC (TPS < 1%) (Keynote 189; PD-L1 screen: 22C3 pharmDx assay) though both PD-L1 groups benefitted from the combination treatment [9].